Single Protein Knockout Keeps Cancer-Fighting CAR T Cells Alive Longer
Disabling the NFIL3 protein prevents CAR T cell exhaustion, boosting tumor-fighting power in animal models of hard-to-treat cancers.
Summary
CAR T-cell therapy has transformed treatment for some blood cancers, but it struggles against solid tumors. Researchers from Columbia University and University Hospital Tübingen have identified a key reason why: a protein called NFIL3 causes these engineered immune cells to burn out over time. By using CRISPR gene-editing to disable the NFIL3 gene, scientists kept CAR T cells active longer, helped them multiply more efficiently, and improved tumor control in mouse models. The discovery, published in Cancer Discovery, could lead to next-generation CAR T therapies that remain potent enough to tackle cancers that currently resist immunotherapy. While still in animal testing, the findings represent a meaningful step toward more durable cancer treatments.
Detailed Summary
CAR T-cell therapy represents one of the most promising frontiers in cancer treatment, but a persistent problem has limited its reach: the engineered immune cells tend to exhaust themselves before finishing the job. A new study identifies a single molecular culprit behind this failure and shows that removing it dramatically improves performance.
Researchers at Columbia University and University Hospital Tübingen screened approximately 400 transcription factors — proteins that regulate gene activity — to find which ones might be undermining CAR T-cell function. They zeroed in on NFIL3, a protein that appears to drive immune cell exhaustion. When NFIL3 was disabled using CRISPR/Cas9 gene-editing, CAR T cells stayed active longer, divided more effectively, and delivered stronger anti-tumor responses across multiple mouse tumor models, including solid tumors that are notoriously difficult to treat.
The significance of this finding lies in its specificity. Rather than broadly re-engineering the immune response, disabling one gene produces measurable, durable improvements. The study, published in the journal Cancer Discovery, was led by Prof. Michel Sadelain, a pioneer of CAR T therapy, alongside Prof. Judith Feucht, who bridges laboratory research with direct patient care in pediatric oncology.
For the longevity-minded reader, cancer remains one of the leading threats to both lifespan and healthspan. Advances that make immunotherapies more effective against solid tumors — which account for the vast majority of cancer deaths — are directly relevant to extending healthy life. NFIL3 inhibition could eventually be incorporated into next-generation CAR T manufacturing protocols.
Important caveats apply. All results are from animal models, and human trials have not yet been conducted. Translation from mouse to human immune systems is complex, and it remains unknown whether NFIL3 deletion causes off-target effects in patients. Independent replication and clinical studies will be essential before this approach reaches the clinic.
Key Findings
- NFIL3 protein drives CAR T-cell exhaustion, reducing long-term cancer-fighting effectiveness in animal models.
- CRISPR knockout of NFIL3 kept CAR T cells active longer and improved tumor control across multiple mouse models.
- Solid tumors, historically resistant to CAR T therapy, showed better responses when NFIL3 was disabled.
- Targeting a single transcription factor may offer a precise, scalable improvement to CAR T manufacturing.
- Findings published in Cancer Discovery by leading CAR T pioneer Michel Sadelain and collaborators.
Methodology
This is a research news summary based on a peer-reviewed study published in Cancer Discovery. The work comes from credible academic institutions — Columbia University and University Hospital Tübingen — and was led by a recognized pioneer in CAR T-cell research. Evidence is preclinical, derived from large-scale transcription factor screening and CRISPR-based mouse model experiments.
Study Limitations
All findings are from animal models; human efficacy and safety data do not yet exist. The article is a news summary and does not detail the full methodology, dosing, or potential off-target effects of NFIL3 deletion. Independent replication in human cell systems and clinical trials will be needed before drawing conclusions about patient benefit.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.